# TROP2

Source: https://onco.cc/targets/trop2/  
OnCo record `trop2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.

## Summary

Trophoblast cell-surface antigen 2 is a transmembrane glycoprotein overexpressed in most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) with low normal-tissue expression. It is not an oncogenic driver; it is a delivery address. Three TROP2 ADCs are approved or in registration (sacituzumab govitecan, datopotamab deruxtecan, sacituzumab tirumotecan) and a TROP2 PET tracer is in development to select patients.

## Fields

- Kind: Target
- Last checked: 2026-10-06
- Tags: adc-target; pet-target
- Symbol: TACSTD2
- Class: surface-antigen
- Biology: Regulates calcium signalling and cell adhesion; overexpression correlates with shorter survival. Expression is heterogeneous within tumours, which limits the value of IHC selection. Internalises on antibody binding and traffics to lysosomes, which is what makes it a good ADC target.
- Where found: Triple-negative breast cancer (~80-90% express); HR+ breast cancer; NSCLC; Urothelial carcinoma; Gastric, pancreatic, endometrial cancers; Triple-negative breast cancer: gene amplification (copy number) 2.5-4.4%

## Notes

- Triple-negative breast cancer: sacituzumab govitecan benefit was seen at high and medium Trop-2 H-score in ASCENT with a low group too small to judge (Bardia 2021); no label requires the test. TACSTD2 amplification is rare, 2.5 to 4.4% (cBioPortal).

## Sources

- UniProt P09758: TACSTD2 (TROP2): https://www.uniprot.org/uniprotkb/P09758/entry
- Bardia et al., ASCENT biomarker analysis (Ann Oncol 2021): https://doi.org/10.1016/j.annonc.2021.06.002
- TRODELVY prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d
- DATROWAY prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0

## Connected records

- biomarkers: [TROP2 expression](https://onco.cc/biomarkers/trop2-expression/)
- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [9MW2921](https://onco.cc/drugs/9mw2921/), [AK146D1](https://onco.cc/drugs/ak146d1/), [ASP2998](https://onco.cc/drugs/asp2998/), [AVZO-103](https://onco.cc/drugs/avzo-103/), [BAT8008](https://onco.cc/drugs/bat8008/), [BCG033](https://onco.cc/drugs/bcg033/), [BHV-1510](https://onco.cc/drugs/bhv-1510/), [BIO-106](https://onco.cc/drugs/bio-106/), [CAN020](https://onco.cc/drugs/can020/), [CATB-101](https://onco.cc/drugs/catb-101/), [CBB-120](https://onco.cc/drugs/cbb-120/), [CTPH-03](https://onco.cc/drugs/ctph-03/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [DB-1305 / BNT325](https://onco.cc/drugs/db-1305/), [EB-NK-301](https://onco.cc/drugs/eb-nk-301/), [ESG401](https://onco.cc/drugs/esg401/), [FDA018-ADC](https://onco.cc/drugs/fda018-adc/), [IBI130](https://onco.cc/drugs/ibi130/), [IBI3014](https://onco.cc/drugs/ibi3014/), [JS108](https://onco.cc/drugs/js108/), [JSKN016](https://onco.cc/drugs/jskn016/), [KH815](https://onco.cc/drugs/kh815/), [LCB84](https://onco.cc/drugs/lcb84/), [MT-302](https://onco.cc/drugs/mt-302/), [PF-06664178](https://onco.cc/drugs/pf-06664178/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [SHR-A1921](https://onco.cc/drugs/shr-a1921/), [STI-3258](https://onco.cc/drugs/sti-3258/), [TROP2 CAR/IL-15 cord-blood NK cells](https://onco.cc/drugs/trop2-car-il15-cord-blood-nk/), [VBC103](https://onco.cc/drugs/vbc103/)
- trials: [A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05923008/), [A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct06902389/), [A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)](https://onco.cc/trials/nct06966700/), [A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors](https://onco.cc/trials/nct06384807/), [A Phase I Study of JS108 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct04601285/), [A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer](https://onco.cc/trials/nct06112379/), [A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care](https://onco.cc/trials/nct07533123/), [A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C](https://onco.cc/trials/nct06564844/), [A Study of AK146D1 for Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07067567/), [A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06929663/), [A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors](https://onco.cc/trials/nct07287995/), [A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06130553/), [A Study of FDA018-ADC in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05174637/), [A Study of GQ1010 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06464055/), [A Study Of PF-06664178 In Patients With Advanced Solid Tumors](https://onco.cc/trials/nct02122146/), [A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)](https://onco.cc/trials/nct06312176/), [A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)](https://onco.cc/trials/nct06841354/), [A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm](https://onco.cc/trials/nct06312137/), [A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors](https://onco.cc/trials/nct05941507/), [A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan](https://onco.cc/trials/nct06417814/), [ASCENT](https://onco.cc/trials/ascent/), [ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)](https://onco.cc/trials/ascent-05/), [Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)](https://onco.cc/trials/nct04639986/), [Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)](https://onco.cc/trials/nct04434040/), [BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)](https://onco.cc/trials/nct07193511/), [Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06454890/), [Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07299747/), [Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)](https://onco.cc/trials/nct05555732/), [DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06953089/), [DIAMOND](https://onco.cc/trials/diamond/), [Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)](https://onco.cc/trials/nct06358430/), [Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection](https://onco.cc/trials/nct05620017/), [First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05438329/), [IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06974812/), [KH815 first-in-human study](https://onco.cc/trials/nct06885645/), [NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)](https://onco.cc/trials/nct06081244/), [NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer](https://onco.cc/trials/nct07178730/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)](https://onco.cc/trials/nct06311214/), [Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)](https://onco.cc/trials/nct06066424/), [Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions](https://onco.cc/trials/nct07631013/), [Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors](https://onco.cc/trials/nct07589530/), [Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum](https://onco.cc/trials/nct07509008/), [Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers](https://onco.cc/trials/nct07553390/), [Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)](https://onco.cc/trials/nct07101432/), [Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05990452/), [Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L](https://onco.cc/trials/nct06350097/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥](https://onco.cc/trials/nct06357533/), [PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease](https://onco.cc/trials/nct07069595/), [Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations](https://onco.cc/trials/nct07628504/), [Sacituzumab Govitecan and Q901 in Advanced TNBC](https://onco.cc/trials/nct07788222/), [Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases](https://onco.cc/trials/nct06238921/), [Sacituzumab Govitecan in Primary HER2-negative Breast Cancer](https://onco.cc/trials/nct04595565/), [Sacituzumab Govitecan In TNBC](https://onco.cc/trials/nct04230109/), [Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P](https://onco.cc/trials/nct06170788/), [Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)](https://onco.cc/trials/nct06393374/), [Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct06074588/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct05347134/), [Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies](https://onco.cc/trials/nct05417594/), [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://onco.cc/trials/nct05489211/), [Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab](https://onco.cc/trials/nct05215340/), [Study of ESG401 in Adults With Solid Tumors](https://onco.cc/trials/nct04892342/), [Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06167317/), [Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer](https://onco.cc/trials/nct06942234/), [Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors](https://onco.cc/trials/nct05969041/), [Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)](https://onco.cc/trials/nct05609968/), [Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment](https://onco.cc/trials/nct04617522/), [Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer](https://onco.cc/trials/nct05922930/), [Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors](https://onco.cc/trials/nct05060276/), [To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct06592417/), [TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer](https://onco.cc/trials/nct07377526/), [Trop2-targeted immunoPET Imaging of Solid Tumors](https://onco.cc/trials/nct06851663/), [TROPiCS-02](https://onco.cc/trials/tropics-02/), [TROPION-Breast03](https://onco.cc/trials/tropion-breast03/), [TROPION-Breast05](https://onco.cc/trials/tropion-breast05/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/), [TROPION-Lung17](https://onco.cc/trials/nct07291037/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/), [Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/), [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/)
- terms: [Antigen](https://onco.cc/terms/antigen/), [HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)](https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/), [Overexpression](https://onco.cc/terms/overexpression/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- ideas: [A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer](https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/), [Alpha radioligands after ADC failure](https://onco.cc/ideas/idea-alpha-after-adc/), [Bispecific antibodies that engage macrophages instead of T cells](https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/), [Dual-payload ADCs in first line to prevent resistance](https://onco.cc/ideas/idea-dual-payload-first/), [Re-map the tumour's surface proteins before choosing the next antibody drug](https://onco.cc/ideas/idea-bio1-antigen-mapping-at-progression/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/), [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/), [Pathos AI](https://onco.cc/companies/pathos-ai/)
- institutions: [Fudan University Shanghai Cancer Center](https://onco.cc/institutions/fuscc/)
- pathways: [DNA replication & origin licensing](https://onco.cc/pathways/dna-replication-licensing/), [Drug efflux pumps (ABC transporters)](https://onco.cc/pathways/drug-efflux-pumps/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/)
- pairings: [TROP2 PET → TROP2 ADC selection](https://onco.cc/pairings/trop2-pet-to-adc/)
- people: [Aditya Bardia](https://onco.cc/people/aditya-bardia/), [Binghe Xu](https://onco.cc/people/xu-binghe/), [Hope S. Rugo](https://onco.cc/people/hope-rugo/), [Joohyuk Sohn](https://onco.cc/people/sohn-joohyuk/), [Sara M. Tolaney](https://onco.cc/people/sara-tolaney/), [Shaoli Song](https://onco.cc/people/song-shaoli/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/)

---
JSON: https://onco.cc/api/v1/entities/trop2.json